A Phase 2 interventional study of AU-011 and SCS Microinjector in Eye Cancer and Primary Cancer, sponsored by Aura Biosciences. Recruiting at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by Aura Biosciences · Phase 2, Interventional, and Treatment
The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
This is an open-label, dose escalation trial designed to assess safety and tolerability of 4 dose strengths and 1-2 cycles of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
26 studies on the registry are indexed under Eye Neoplasms; 6 are open to participants now.
This study's planned enrollment of 24 is below the median of 40 across 15 interventional studies indexed under Eye Neoplasms.
Browse Eye Neoplasms studies →Aura Biosciences is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
1 Cycle AU-011 with a dose of 80 micrograms
Drug: AU-011 · Device: SCS Microinjector · Device: Laser
1 Cycle AU-011 with a dose of 140 micrograms
Drug: AU-011 · Device: SCS Microinjector · Device: Laser
1 Cycle AU-011 with a dose of 200 micrograms
Drug: AU-011 · Device: SCS Microinjector · Device: Laser
2 Cycles AU-011 with a dose of 200 micrograms
Drug: AU-011 · Device: SCS Microinjector · Device: Laser
Subjects that meet trial inclusion, but do not meet criteria for enrollment into the bel-sar treatment cohorts, may be enrolled in this cohort. The observational cohort will not receive bel-sar treatment.
1 Cycle AU-011 with a dose of 40 micrograms
Drug: AU-011 · Device: SCS Microinjector · Device: Laser
2 Cycles AU-011 with a dose of 40 micrograms
Drug: AU-011 · Device: SCS Microinjector · Device: Laser
AU-011 Via Suprachoroidal Administration with laser treatment
Suprachoroidal Injection Device
Laser Administration
Change from baseline in choroidal tumor thickness on B-scan ultrasonography (B-scan) 4 weeks after completion of treatment.
B-Scan Ultrasonography
Time frame: 4 weeks after completion of treatment
Change from baseline in choroidal tumor largest basal diameter (LBD) on fundus photos 4 weeks after completion of treatment.
Fundus photos
Time frame: 4 weeks after completion of treatment
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aura Biosciences